Who is moving to which position
Resolved 14 May 2026Incoming appointee
6 itemsDeparting officer
1 item“Next role stated” means the document names the position the person holds after stepping down. It does not necessarily mean they are leaving the company.
Retirement upon expiration of the term of office
Not scheduled to remain on the Board of Directors. However, the new positions effective 14 May 2026 are stated as Representative Director and President of 株式会社S-Quatre and Director of Kidswell Bio Corporation.
Organizational and personnel changes will be implemented to strengthen coordination between management strategy and research and development strategy through the reorganization of the research and development structure, and to operate the research and development functions in an integrated manner in preparation for the Company’s upcoming clinical development phase.
Through global project management activities in pharmaceutical development, the candidate has been involved in a broad range of development stages, from nonclinical research through clinical development and approval. The candidate is being nominated as a person who can lead the integrated operation of the research and development functions and advance the cell therapy business within the Company’s group under the organizational changes to the research and development structure accompanying the transition to this development phase.
The functions of the Research Headquarters, Development Headquarters and Production Headquarters have been integrated, and the Research and Development Headquarters has been established.
| Item | Details |
|---|---|
| Resolution date | 14 May 2026 |
| Scheduled Appointment Date | 29 June 2026 (the scheduled date of the 26th Annual General Meeting of Shareholders). Subject to election at the General Meeting of Shareholders |
| Date of departure | 29 June 2026 (予定) |
| Name of appointee | Kurebayashi Shinya (紅林伸也), Eiki Norikazu (栄木憲和), Nishioka Sachiko (西岡佐知子), Masubuchi Noriko (桝渕紀子), Sakabe Munetaka (坂部宗親), Kawakami Masayuki (川上雅之) |
| Appointee's new position | Representative Director and President; Executive Officer, Chief Executive Officer, Chief Communications Officer and Head of the Corporate Strategy Headquarters, Director (reappointment), Director (reappointment), Executive Officer, Head of the Research and Development Headquarters, Executive Officer, Deputy Head of the Research and Development Headquarters; Director, 株式会社S-Quatre, Executive Officer, Deputy Head of the Research and Development Headquarters; Director, 株式会社S-Quatre |
| Appointee's previous position | Representative Director and President; Executive Officer, Chief Executive Officer, Chief Communications Officer and Head of the Corporate Strategy Headquarters, Directors, Directors, Head of the Translational Research Department, Development Headquarters, Executive Officer, Head of Production Division, Executive Officer, Head of the Development Headquarters; Director, 株式会社S-Quatre |
| Year the appointee joined the Company | 2025 (Masubuchi Noriko (桝渕紀子); not disclosed for the others) |
| Name of departing officer | Mitani Yasuyuki (三谷泰之) |
| Former position of departing officer | Directors |
| New position of departing officer | Retirement (expiration of term of office) |
| Reason for departure | Retirement upon expiration of the term of office |
| Whether the incumbent will remain in office | Not scheduled to remain on the Board of Directors. However, the new positions effective 14 May 2026 are stated as Representative Director and President of 株式会社S-Quatre and Director of Kidswell Bio Corporation. |
| Reason for change | Organizational and personnel changes will be implemented to strengthen coordination between management strategy and research and development strategy through the reorganization of the research and development structure, and to operate the research and development functions in an integrated manner in preparation for the Company’s upcoming clinical development phase. |
| Reasons for appointment | Through global project management activities in pharmaceutical development, the candidate has been involved in a broad range of development stages, from nonclinical research through clinical development and approval. The candidate is being nominated as a person who can lead the integrated operation of the research and development functions and advance the cell therapy business within the Company’s group under the organizational changes to the research and development structure accompanying the transition to this development phase. |
| Number of directors after the change | 3 directors (including 2 outside directors) |
| Details of organizational changes | The functions of the Research Headquarters, Development Headquarters and Production Headquarters have been integrated, and the Research and Development Headquarters has been established. |
| Subject to Approval by the General Meeting of Shareholders | Required. The proposal, “Election of 3 Directors,” will be submitted to the 26th Annual General Meeting of Shareholders scheduled for 29 June 2026. |
Items this document does not state (4)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The changes are intended to strengthen coordination between management strategy and research and development strategy through the reorganization of the research and development structure, and to operate the research and development functions in an integrated manner in preparation for the Company’s upcoming clinical development phase. They are also intended to optimize the clinical development structure for the cell therapy business and rebuild the human capital management and data-sharing and management structures.